US · Healthcare · Biotechnology
EPS came in at -0.40 against a street estimate of -0.46 — a beat of 13.0%.
Analysts rate Contineum Therapeutics, Inc. Class A Common Stock a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $23.43.
| Fund | Stake |
|---|---|
| Suvretta Capital Management, LLC | 7.55% |
| HHG PLC | 7.27% |
| Johnson & Johnson | 5.26% |
| Franklin Templeton Inc | 4.89% |
| Balyasny Asset Management LLC | 4.48% |
| Baker Bros Advisors LP | 3.78% |
| RA Capital Management, LLC | 3.44% |
| Perceptive Advisors LLC | 3.34% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Contineum Therapeutics, Inc. Class A Common Stock — free to start.
Google PlayApp StoreData updated 2026-09-18.